Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Investment of Approximately USD 8.8 Million for New Drug Development Against Malaria to Partners Including Marubeni and Eisai


      News provided by

      GHIT Fund

      Dec 13, 2023, 23:00 ET

      Share this article

      Share this article


      • First investment in a Japanese trading company and a Chinese pharma company.
      • Accelerating new drug development by investing in late-phase clinical trials.

      TOKYO, Dec. 13, 2023 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately 1.3 billion yen (US$8.8 million1) for the development of new drugs for malaria and Chagas disease.2

      Malaria is an infectious parasitic disease transmitted by mosquitos that affects approximately 250 million people annually and was responsible for approximately 620,000 deaths in 2021.3 The African region constitutes a staggering 95% of global malaria cases, and children under the age of 5 account for 80% of all malaria deaths in this region.

      The GHIT Fund invests in new product development with the aim of contributing to global health by facilitating collaborations between Japanese technology and innovation and global institutions to address these neglected infectious diseases. This is the first investment by the GHIT Fund in a general trading company, Marubeni Corporation (Marubeni), and a pharmaceutical company in China, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (FOSUN PHARMA), with the aim of accelerating the development of new drugs by focusing on investments in late-phase clinical trials.

      First investment in a Japanese trading company and a Chinese pharma company — new malaria drug in a phase III trial by Marubeni, Fosun Pharma, MORU, and MMV
      The GHIT Fund will invest approximately 500 million yen (US$3.3 million1) in a clinical phase III trial for a triple artemisinin combination drug against malaria, in partnership with a leading Japanese integrated trading and investment business conglomerate, Marubeni, a major Chinese pharmaceutical and health care company, FOSUN PHARMA, a Thailand-based research collaboration of universities, Mahidol-Oxford Tropical Medicine Research Unit (MORU), and the product development partnership Medicines for Malaria Venture (MMV), which provides technical support and market access expertise.  

      This drug candidate should have a significant public health benefit as it is expected to play an important role in the fight against artemisinin partial resistance (ART-R), which is now observed widely in the Greater Mekong Subregion (GMS) of Southeast Asia4 and to some extent in several African countries, including Rwanda and Uganda. Importantly, the project includes the development of a co-formulated child-friendly version, given that most malaria cases are in children.3

      800-million-yen investment in a phase IIb study of the new anti-malarial drug candidate SJ733 as a radical cure for P. vivax
      The GHIT Fund will also invest approximately 800 million yen (US$5.4 million1) in the anti-malarial drug project by Eisai Co., Ltd. and the University of Kentucky to develop a radical cure for P. vivax malaria. SJ733, an antimalarial drug candidate, has completed a Phase IIa trial for single administration and has shown efficacy and tolerability against P. vivax malaria. With this new investment, the project aims to shorten the treatment period by using SJ733 in combination with the existing drug tafenoquine.

      Dr. Osamu Kunii, CEO of the GHIT Fund, said "We are very excited to have Marubeni and FOSUN PHARMA as our new product development partners. It is an important step forward to invest in the development of antimalarial drugs in late-phase clinical trials to advance commercialization. The number of malaria cases and deaths in children under 5 years old is an urgent issue. This investment will make a significant contribution to reducing the burden of malaria globally, especially among young children."

      In addition, the GHIT Fund will invest approximately 16 million yen (US$0.1 million1) in Nagasaki University and Drugs for Neglected Diseases initiative (DNDi) for a screening project against Chagas disease, which is one of the neglected tropical diseases.  

      As of December 14, 2023, there are 50 ongoing projects, including 19 discovery projects, 18 preclinical projects and 13 clinical trials5 in the GHIT Fund's portfolio. The total amount of investments since 2013 is 31.6 billion yen (US$211 million).


      1 USD1 = JPY149.52, the approximate exchange rate on October 31, 2023.
      2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-001 for the Product Development Platform, which was open for applications from November 2022 to July 2023.
      3 WHO (World Health Organization): https://www.who.int/news-room/fact-sheets/detail/malaria
      4 GMS comprises Cambodia, Lao People's Democratic Republic (Lao PDR), Myanmar, Vietnam, Thailand, and the People's Republic of China (PRC, specifically Yunnan Province and Guangxi Zhuang Autonomous Region).
      5 This number includes the projects in the registration phase.

      The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
      https://www.ghitfund.org/en

      Appendix 1. Project Details    

      G2022-205

      Project Title

      Evaluation and preparation for deployment of an Artemether-Lumefantrine-
      Amodiaquine Fixed-Dose Combination to counter antimalarial drug resistance in
      Plasmodium falciparum malaria

      Collaboration

      Partners

      1. Marubeni Corporation

      2. Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (FOSUN PHARMA)

      3. Mahidol-Oxford Tropical Medicine Research Unit (MORU)

      4. Medicines for Malaria Venture (MMV)

      Disease

      Malaria

      Intervention

      Drug

      Stage

      Clinical Phase III, Licensure

      Awarded Amount

      ¥504,325,357 (US$3.3million)

      Status

      New project

      Summary

      [Project objective]

      1. Evaluate the safety, tolerability and efficacy of ALAQ-FDC developed and produced by
      FOSUN PHARMA compared to the current first-line treatments AL and ASAQ, in areas
      with different patterns of antimalarial drug resistance.

      2. Compare the post-treatment prophylactic effect of ALAQ-FDC with AL and ASAQ.

      3. Assess potential drug-drug interactions in ALAQ-FDC in clinical use.

      4. Explore potential strategies for the successful registration, deployment and
      commercialization of ALAQ-FDC in participating countries.

      5. Explore the marketing positioning of ALAQ-FDC to facilitate the introduction of ALAQ-
      FDC in malaria endemic countries

      [Project design]

      The safety, tolerability, efficacy and pharmacokinetic/dynamic aspects of ALAQ-FDC will
      be studied in a randomized controlled non-inferiority trial comparing ALAQ-FDC to the
      ACTs artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) (with single-
      low dose primaquine in some sites) for the treatment of uncomplicated Plasmodium
      falciparum malaria. The study will be conducted at sites in Rwanda, Uganda, Angola,
      Nigeria and Thailand.

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/215/en

      G2022-218

      Project Title

      Combination of SJ733 with Tafenoquine as a Possible Radical Cure for P. vivax Malaria.

      Collaboration

      Partners

      1. Eisai Co., Ltd.

      2. University of Kentucky

      Disease

      Malaria

      Intervention

      Drug

      Stage

      Clinical Phase IIb

      Awarded Amount

      ¥807,182,400 (US$5.4 million)

      Status

      Continued project

      Summary

      [Project objective]

      The overall objective of this project is to examine the clinical safety and efficacy of the
      combination of SJ733 and TQ for radical cure of P. vivax malaria. The purpose is to
      develop an SJ733-TQ combination drug suitable for treatment of all patients with
      uncomplicated P. vivax malaria. The targeted results for this study are data that support
      1 to 3 doses of an SJ733-TQ fixed dose combination for radical cure of P. vivax mono-
      infected patients. 

      [Project design]

      First, we will consider toxicology associated with administration of the combination of
      SJ733 and TQ to support the proposed Phase IIb studies. Next, we will carry out a clinical
      trial to establish safety and efficacy of a fixed-dose combination of SJ733-TQ in adults
      with P. vivax malaria mono-infection to examine the safety and efficacy of the
      combination of SJ733 and TQ in uncomplicated P. vivax malaria mono-infection in
      Peruvian adult patients. The primary objectives are to assess the safety, tolerability,
      efficacy, and pharmacokinetics of an orally administered combination of SJ733 and TQ.
      Concurrently, we will explore options to reduce the overall cost of goods of SJ733. 

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/216/en

      S2023-121

      Project Title

      HTS for discovery of new drugs for Chagas disease

      Collaboration

      Partners

      1. Nagasaki University

      2. Drugs for Neglected Diseases initiative (DNDi)

      Disease

      Chagas disease

      Intervention

      Drug

      Stage

      Screening

      Awarded Amount

      ¥16,089,533 (US$0.1 million)

      Status

      New project

      Summary

      [Project objective]

      The main objective of this research project is to identify novel and potent antichagasic
      compounds from selected chemical library subsets from the Center for Supporting Drug
      Discovery and Life Science Research, Osaka University that meets the GHIT/DNDi criteria.

      [Project design]

      A total of seven chemical library subsets from the Center for Supporting Drug Discovery
      and Life Science Research, Osaka University (Osaka Library, total number 62,029
      compounds) will be tested in a cell-based high-throughput screening system against
      intracellular amastigote stage of a T. cruzi strain that were genetically engineered to
      express the firefly luciferase gene. The cytotoxicity against human cell lines as well as the
      biological activity against four major T. cruzi strains of the primary hits will be evaluated.

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/217/en

      *All amounts are listed at an exchange rate of USD1 = JPY149.52, the approximate exchange rate on October 31, 2023.

      Appendix 2. Investment Overview (as of December 14, 2023)

      Investments to date 
      Total investments: 31.6 billion yen (US$211 million1)
      Total invested projects: 123 (50 active projects and 73 completed projects)

      To learn more about GHIT Fund's investments, please visit
      Investment Overview: https://www.ghitfund.org/investment/overview/en
      Portfolio: https://www.ghitfund.org/investment/portfolio/en
      Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
      Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en

      For more information, contact:
      Katy Lenard at +1-301-280-5719 or [email protected]
      Mina Ohata at +81-36441-2032 or [email protected]

      SOURCE GHIT Fund

      Modal title

      Also from this source

      Total Investment of Approx. USD 6.8 Million in Product Development for Malaria, NTDs and Other Emerging & Re-emerging Infectious Diseases Such as Ebola Disease

      The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million1) in nine...

      GHIT Fund Launches "NTDpedia" to Help Turn Apathy Into Action Against Neglected Tropical Diseases

      The Global Health Innovative Technology (GHIT) Fund announced the launch of "NTDpedia: Your Guide to Neglected Tropical Diseases." Designed as an...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Infection Control

      Infection Control

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.